Phyllis Schlafly

Last year, the FDA inspected only 30 foreign drug manufacturing facilities. The FDA estimates the number of drug factories exporting drugs to the United States could be anywhere from 3,000 to 6,800, and the FDA has no idea how many have never been inspected.

The GAO reported that it would take 27 years to inspect every foreign plant that exports medical devices to the United States such as pacemakers and defibrillators. Over the last six years, the FDA inspected only 64 of the 700 plants that produce medical devices.

Unlike domestic inspections, the FDA does not arrive unannounced at a foreign factory; the Chinese have the opportunity to prepare for the inspection. The FDA does not have its own translators but relies on translators provided by the Chinese.

The FDA inspects only about 7 percent of foreign establishments a year. The FDA admits that there are at least 2,133 foreign drug factories for which the FDA could not identify any previous inspection.

The FDA does not have a dedicated staff to conduct foreign inspections but relies on domestic inspectors to volunteer. U.S. inspectors must adhere to an itinerary (presumably arranged by the foreign government) so that multiple inspections can be made on the same trip, and an inspection cannot be extended if problems are discovered.

The entire process of registering facilities that manufacture drugs for export is subject to all kinds of manipulation. There is no system for checking current accuracy or identifying and correcting errors.

The major problem is not the FDA but the multinationals' passion to make free trade a policy that not only locks us into trade agreements that discriminate against U.S. manufacturing and jobs but even trumps U.S. health and safety standards.

Free trade is not only bringing us contaminated drugs and foods, but soon could bring us the products of embryonic stem cell transfers (aka cloning). The Chinese government is financing a new laboratory to conduct research on stem cells, the nuclear transfer and reprogramming of cells, and other cell-engineering innovations.

So, there need be no more demands for U.S. funding of embryonic stem cell research. The globalists can partner with Chinese-funded stem cell factories, like the new stem-cell agreement between Beike Biotechnology and Tsinghua University's Shenzhen Graduate School.

Phyllis Schlafly

Phyllis Schlafly is a national leader of the pro-family movement, a nationally syndicated columnist and author of Feminist Fantasies.
TOWNHALL DAILY: Be the first to read Phyllis Schlafly‘s column. Sign up today and receive daily lineup delivered each morning to your inbox.